151 related articles for article (PubMed ID: 37261705)
21. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Wang J; Jiang B; Jiang Q; Lu J; Zhu HH; Yang SM; Zhao T; Wen L; Bao L; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):194-200. PubMed ID: 27033755
[TBL] [Abstract][Full Text] [Related]
22. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Rastogi P; Anderson SJ; Bear HD; Geyer CE; Kahlenberg MS; Robidoux A; Margolese RG; Hoehn JL; Vogel VG; Dakhil SR; Tamkus D; King KM; Pajon ER; Wright MJ; Robert J; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2008 Feb; 26(5):778-85. PubMed ID: 18258986
[TBL] [Abstract][Full Text] [Related]
23. Postmastectomy radiotherapy and concomitant adjuvant chemotherapy versus adjuvant chemotherapy alone in premenopausal breast cancer patients with positive axillary nodes.
Micheletti E; La Face B; Huscher A; Catalano G; Ambrosi E; Marini G; Simoncini E
Tumori; 1998; 84(6):652-8. PubMed ID: 10080670
[TBL] [Abstract][Full Text] [Related]
24. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
García-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gómez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortés-Funes H
J Clin Oncol; 1997 Oct; 15(10):3178-84. PubMed ID: 9336353
[TBL] [Abstract][Full Text] [Related]
25. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection.
Seinen JM; Styring E; Verstappen V; Vult von Steyern F; Rydholm A; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2012 Aug; 19(8):2700-6. PubMed ID: 22466664
[TBL] [Abstract][Full Text] [Related]
26. Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials.
Chen H; Qian X; Tao Y; Wang D; Wang Y; Yu Y; Yao H
Breast; 2023 Oct; 71():1-12. PubMed ID: 37429049
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
[TBL] [Abstract][Full Text] [Related]
28. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
29. Angiosarcoma associated with radiation therapy after treatment of breast cancer. Retrospective study on ten years.
Verdin V; Mattart L; Cusumano PG; De Hertogh O; De Meester C; Francart D; Kirova YM; Nelissen X; Sacino F; Vanderick J; Weerts J; Markiewicz S
Cancer Radiother; 2021 Apr; 25(2):114-118. PubMed ID: 33487559
[TBL] [Abstract][Full Text] [Related]
30. Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC).
Taffurelli M; Pellegrini A; Meattini I; Orzalesi L; Tinterri C; Roncella M; Terribile D; Caruso F; Tazzioli G; Pollini G; Friedman D; Mariotti C; Cianchetti E; Cabula C; Thomas R; Cedolini C; Rovera F; Grassi M; Lucani G; Cappella A; Bortul M; Stacul G; Scarabeo F; Procaccini E; Galimberti V
Breast; 2019 Jun; 45():56-60. PubMed ID: 30877870
[TBL] [Abstract][Full Text] [Related]
31. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
[TBL] [Abstract][Full Text] [Related]
32. Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients.
Gentile D; Sagona A; De Carlo C; Fernandes B; Barbieri E; Di Maria Grimaldi S; Jacobs F; Vatteroni G; Scardina L; Biondi E; Vinci V; Trimboli RM; Bernardi D; Tinterri C
Breast; 2023 Jun; 69():323-329. PubMed ID: 37001289
[TBL] [Abstract][Full Text] [Related]
33. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
[TBL] [Abstract][Full Text] [Related]
34. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review.
Depla AL; Scharloo-Karels CH; de Jong MAA; Oldenborg S; Kolff MW; Oei SB; van Coevorden F; van Rhoon GC; Baartman EA; Scholten RJ; Crezee J; van Tienhoven G
Eur J Cancer; 2014 Jul; 50(10):1779-1788. PubMed ID: 24731859
[TBL] [Abstract][Full Text] [Related]
35. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H; Yamamoto Y; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Ohtani S; Kashiwaba M; Taira N; Toyama T; Fujisawa T; Masuda N; Shibahara Y; Sasano H; Yamaguchi T
Breast Cancer Res Treat; 2023 Jun; 199(2):231-241. PubMed ID: 36947277
[TBL] [Abstract][Full Text] [Related]
37. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
[TBL] [Abstract][Full Text] [Related]
38. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
39. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
40. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
Seddik Y; Brahmi SA; Afqir S
Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
